Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleFocus on Molecular Imaging

Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy

Yubin Miao and Thomas P. Quinn
Journal of Nuclear Medicine March 2021, 62 (3) 313-318; DOI: https://doi.org/10.2967/jnumed.120.243840
Yubin Miao
1Department of Radiology, School of Medicine, University of Colorado Denver, Aurora, Colorado; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas P. Quinn
2Department of Biochemistry, University of Missouri–Columbia, and Harry S. Truman Veterans’ Hospital, Columbia, Missouri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    (A) Schematic illustration of MC1R-avid radiolabeled α-MSH peptide to detect B16/F1 flank melanoma (T) and B16/F10 pulmonary metastatic melanoma (Mets) in mice and melanoma metastases in a melanoma patient. BM, LM, CM, and IM represent melanoma metastases in brain, lung, connective tissue, and intestines, respectively. (B) Representative α-MSH peptides. (Human and animal images reprinted with permission of 5, 19, and 20.)

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Molecular model of α-MSH-PEG-Cy5-C′ dot. Silicon, oxygen, carbon, nitrogen, and sulfur atoms are colored purple, red, gray, blue, and yellow, respectively. DOTA chelator was attached to epsilon amine of d-Lys residue for 177Lu and 225Ac radiolabeling. (Reprinted with permission of 29.)

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    (A) Schematic structure of DOTA-PEG4-LLP2A. (B) Biodistribution of 177Lu/68Ga-DOTA-PEG4-LLP2A and survival curves for treatments with 177Lu-DOTA-PEG4-LLP2A alone and combined with immune checkpoint inhibitors. (Reprinted with permission of 38 and 39.)

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
Yubin Miao, Thomas P. Quinn
Journal of Nuclear Medicine Mar 2021, 62 (3) 313-318; DOI: 10.2967/jnumed.120.243840

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
Yubin Miao, Thomas P. Quinn
Journal of Nuclear Medicine Mar 2021, 62 (3) 313-318; DOI: 10.2967/jnumed.120.243840
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MC1R-TARGETED DIAGNOSTIC AND THERAPEUTIC α-MELANOCYTE–STIMULATING HORMONE (α-MSH) PEPTIDES
    • MC1R-TARGETED α-MSH-FUNCTIONALIZED DIAGNOSTIC AND THERAPEUTIC C′ DOTS
    • VLA-4–TARGETED DIAGNOSTIC AND THERAPEUTIC LLP2A PEPTIDES
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Pre-clinical Evaluation of Biomarkers for Early Detection of Nephrotoxicity Following Alpha-particle Radioligand Therapy
  • Google Scholar

More in this TOC Section

  • From Genome to Phenome: Opportunities and Challenges of Molecular Imaging
  • Imaging the Activity of Efflux Transporters at the Blood–Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria
  • Molecular Imaging of Pulmonary Fibrosis
Show more Focus on Molecular Imaging

Similar Articles

Keywords

  • melanocortin-1 receptor
  • very late antigen-4
  • peptide radiopharmaceuticals
  • Cornell prime dots
  • melanoma imaging and therapy
SNMMI

© 2025 SNMMI

Powered by HighWire